ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "interferon"

  • Abstract Number: 0946 • ACR Convergence 2020

    ENPP1 Regulates UV Light Triggered Type I Interferon Response in the Skin

    Sladjana Skopelja-Gardner1, Joyce Tai2, Xizhang Sun2 and Keith Elkon2, 1University of Washington, Seattle, WA, 2University of Washington, Seattle

    Background/Purpose: Systemic lupus erythematosus (SLE) patients have a prominent type I interferon (IFN-I) signature in both the lesional and non-lesional skin. We recently showed that…
  • Abstract Number: 1818 • ACR Convergence 2020

    IgG and IgA Autoantibodies Against L1 ORF1p Expressed in Granulocytes Correlate with Granulocyte Consumption and Disease Activity in Pediatric Systemic Lupus Erythematosus

    Kennedy Ukadike1, Kathryn Ni1, Victoria Carter1, Martin Taylor2, John LaCava3, Lauren Pachman4, Xiaoxing Wang1, Mary Eckert5, Anne Stevens1, Christian Lood1 and Tomas Mustelin1, 1University of Washington, Seattle, WA, 2Massachusetts General Hospital, Boston, MA, 3Rockefeller University, New York, NY, 4Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL, 5Seattle Children's Hospital, Seattle, WA

    Background/Purpose: To quantitate autoantibodies against the RNA-binding p40 (ORF1p) protein encoded by the L1 retroelement, expression of p40 itself, and markers of neutrophil death in…
  • Abstract Number: 0074 • ACR Convergence 2020

    The Intracellular DNA Sensor STING Protects Against Bone Loss Through Regulation of Type I Interferons

    Susan MacLauchlan1, Catherine Manning2, Sijia Chen3, Katherine Fitzgerald4, Shruti Sharma5 and Ellen Gravallese1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women’s Hospital, Boston, 3Brigham and Women's Hospital, Boston, 4University of Massachusetts medical school, Worcester, MA, 5Tufts University, Boston, MA

    Background/Purpose: The intracellular DNA sensor Stimulator of Interferon Genes (STING) is essential for detection of viral and bacterial pathogen DNA. As with other pathways in…
  • Abstract Number: 0957 • ACR Convergence 2020

    Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis

    Bhargavi Duvvuri1, Lauren Pachman2, Richard Moore1, Stephen Doty3 and Christian Lood1, 1University of Washington, Seattle, WA, 2Department of Pediatrics, Northwestern University Feinberg School of Medicine; The Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Rheumatology; The CureJM Center of Excellence in Juvenile Myositis Research and Care, The Stanley Manne Children's Research Center of Chicago, Lake Forest, IL, 3The Hospital for Special Surgery, New York

    Background/Purpose: Calcinosis, the accumulation of calcium crystals in soft tissues, is often a locus of infection and a debilitating manifestation of chronic juvenile dermatomyositis (JDM),…
  • Abstract Number: 1827 • ACR Convergence 2020

    Flare Reduction and Oral Corticosteroid Taper in Patients with Active SLE Treated with Anifrolumab in 2 Phase 3 Trials

    Richard Furie1, Eric Morand2, Anca Askanase3, Ed Vital4, Joan Merrill5, Rubana Kalyani6, Gabriel Abreu7, Lilia Pineda6 and Raj Tummala6, 1Zucker School of Medicine at Hofstra/Northwell, Great Neck, 2Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 3Columbia University College of Physicians and Surgeons, New York, 4University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 5Oklahoma Medical Research Foundation, Oklahoma City, 6BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, 7BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    Background/Purpose: Objectives of long-term SLE management are not only to reduce disease activity, but also to prevent flares and minimize exposure to oral corticosteroids (OCS),…
  • Abstract Number: 0076 • ACR Convergence 2020

    The Role of Interferon Kappa in Psoriasis

    Mehrnaz Gharaee-Kermani1, Shannon Estadt2, Sonya Wolf-Fortune1, Jianhua Liu1, Tamra Reed3, Johann Gudjonsson4 and J. Michelle Kahlenberg5, 1University of Michigan, Ann Arbor, MI, 2University of Michigan, Ypsilanti, MI, 3University of Michigan, Ann Arbor, 4University of Michigan, Ann ArborUniversity of Michigan, 5Division of Rheumatology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Psoriasis is a common, chronic inflammatory autoimmune skin diseases characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of inflammatory cells. Early infiltration…
  • Abstract Number: 0986 • ACR Convergence 2020

    BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus

    Victoria Werth1, Richard Furie2, Juanita Romero-Díaz3, Sandra Navarra4, Kenneth Kalunian5, Ronald van Vollenhoven6, Filippa Nyberg7, Benjamin Kaffenberger8, Saira Sheikh9, Goran Radunovic10, Xiaobi Huang11, Hua Carroll12, Francois Gaudreault12, Adam Meyers11, Catherine Barbey13, Cristina Musselli11 and Nathalie Franchimont11, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 2Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 3Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 4University of Santo Tomas, Manila, Philippines, 5University of California San Diego, La Jolla, CA, 6Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 7Karolinska University Hospital, Stockholm, Sweden, 8Ohio State University, Columbus, OH, 9Division of Rheumatology, Allergy and Immunology, University of North Carolina, Chapel Hill, NC, 10Institute of Rheumatology, University of Belgrade, Belgrade, Serbia, 11Biogen, Cambridge, MA, 12Biogen, Cambridge, 13Biogen, Baar, Switzerland

    Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…
  • Abstract Number: 1828 • ACR Convergence 2020

    Comprehensive Efficacy of Anifrolumab Across Organ Domains in Patients with Active SLE: Pooled Data from 2 Phase 3 Trials

    Eric Morand1, Richard Furie2, Ian Bruce3, Ed Vital4, Maria Dall'Era5, Emmanuelle Maho6, Lilia Pineda7 and Raj Tummala7, 1Monash University, Melbourne, Australia, 2Zucker School of Medicine at Hofstra/Northwell, Great Neck, 3Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 5Division of Rheumatology, University of California, San Francisco, CA, 6BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, 7BioPharmaceuticals R&D, AstraZeneca, Gaithersburg

    Background/Purpose: SLE is a heterogeneous autoimmune disease with clinical manifestations across multiple organ systems. In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab treatment resulted…
  • Abstract Number: 0171 • ACR Convergence 2020

    Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, T Cells, B Cells, and NK Cells in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI

    Jacob Mitchell1, Sara Alehashemi2, Bernadette Marrero3, Yan Huang4, Sofia Torreggiani1, Lena Bichell1, Gina Montealegre Sanchez5, Raphaela Goldbach-Mansky6 and Adriana de Jesus7, 1Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 2Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Clarksville, MD, 3Computational Systems Biology Section/NIAID/NIH, Bethesda, MD, 4NIH, Bethesda, 5NIAID/NIH, Rockville, MD, 6Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD, 7Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD

    Background/Purpose: The disease progression of patients (pts.) with type-I interferon (IFN)-mediated diseases undergoing treatment with JAK1 and JAK2 inhibitors is monitored in part by measuring…
  • Abstract Number: 0990 • ACR Convergence 2020

    Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors

    Jennifer Barnas1, Jennifer Albrecht1 and Jennifer Anolik1, 1University of Rochester Medical Center, Rochester, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by antinuclear autoantibodies produced by plasma cells.  Type I interferon (IFN) are cytokines which…
  • Abstract Number: 1834 • ACR Convergence 2020

    Biomarker Analysis of IFN-I Modulation in JNJ-839: First-in-Human Study for Systemic Lupus Erythematosus

    Ashley Orillion1, Loqmane Seridi1, Matteo Cesaroni2, Jessica Schreiter1, Jacqueline Benson3, William Stohl4, Walter Winn Chatham5, Richard Alan Furie6, Thi-Sau Migone7, Stanley Marciniak1, Zhenling Yao1, Bhaskar Srivastava1, Marc Chevrier2 and Jarrat Jordan1, 1Janssen Research & Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Spring House, 3Janssen Research & Development, LLC, South San Francisco, CA, 4University of Southern California Keck School of Medicine, Los Angeles, CA, 5University of Alabama at Birmingham, Birmingham, AL, 6Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, 7Independent Consultant, Spring House

    Background/Purpose: JNJ-839 is a fully human neutralizing antibody selective to human IFN-ω and IFN-α subtypes. Here we report the exploratory biomarker analyses of a Phase…
  • Abstract Number: 0282 • ACR Convergence 2020

    Expression of the cGAMP Transporter SLC19A1 Is Altered in Systemic Lupus Erythematosus

    Jeong Min Yu1, Gantsetseg Tumurkhuu2, Erica Montano2, Gabriela de los Santos2, Daniel J Wallace2, Mariko Ishimori3 and Caroline Jefferies1, 1Cedars-Sinai Medical Center, West Hollywood, CA, 2Cedars-Sinai Medical Center, Los Angeles, 3Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Inappropriate sensing of nucleic acids leading to enhanced type I interferon (IFN) induction is a hallmark of SLE, contributing to breakdown of immune tolerance…
  • Abstract Number: 0992 • ACR Convergence 2020

    Impact of Selective Inhibitors of Nuclear Export on SLE Plasma Cells Is Modulated by the BM Microenvironment

    Neha Nandedkar-Kulkarni1, Nida Meednu2, Jennifer Albrecht2, Jennifer Barnas2, Douglas Widman3 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical center, Rochester, NY, 3Karyopharm Therapeutics, Newton, MA

    Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells play a key…
  • Abstract Number: 1949 • ACR Convergence 2020

    CB2 Receptor Distribution and Effects of LenabasumTM in Dermatomyositis In Vitro

    Spandana Maddukuri1, Jay Patel2, Christina Bax3, Maria Wysocka3 and Victoria Werth4, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 3University of Pennsylvania, Department of Dermatology, Philadelphia, 4University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia

    Background/Purpose: Dermatomyositis (DM) patients report poor quality of life due to disease activity and persistent itch. Lenabasum is an oral non-immunosuppressive, non-psychoactive cannabinoid type 2…
  • Abstract Number: 0284 • ACR Convergence 2020

    Oxidative DNA Damage Accelerates Skin Inflammation in Pristane-induced Lupus Model

    Gantsetseg Tumurkhuu1, Shuang Chen2, Erica Montano1, Malcolm Lane2, Michifumi Yamashita2, Janet Markman2, Luz Blanco3, Mariana Kaplan4, Kenichi Shimada2, Timothy Crother2, Mariko Ishimori2, Daniel J Wallace1, Caroline Jefferies5 and Moshe Arditi2, 1Cedars-Sinai Medical Center, Los Angeles, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 5Cedars-Sinai Medical Center, West Hollywood, CA

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease in which type I interferons (IFN) play a key role. The IFN response can…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.